Brief introduction to the mechanism of action of filgotinib

Filgotinib is a selective Januskinase1 (JAK1) inhibitor, which is a targeted small molecule immunomodulatory drug. JAK is a type of enzyme that plays a key role in immune signal transduction. JAK1 is particularly involved in the signal transduction of a variety of pro-inflammatory cytokines. Figotinib selectively inhibits JAK1, thereby blocking the signaling pathways of key inflammatory factors, reducing the production and release of inflammatory mediators, and achieving therapeutic effects of controlling inflammation and alleviating symptoms.

This drug is mainly used to treat autoimmune diseases such as active moderate to severe rheumatoid arthritis. In these diseases, the immune system goes awry and attacks its own tissues, causing chronic inflammation and joint damage. By precisely intervening in JAK1-related pathways, filgotinib effectively inhibits excessive activation of immune responses, helps reduce joint swelling, pain, morning stiffness and other symptoms, and delays disease progression.

Compared with other JAK inhibitors, filgotinib is more selective for JAK1 and more selective for JAK2, The inhibitory effects of span>JAK3 and TYK2 are weak, so they may have better safety while controlling inflammation, especially in reducing hematological side effects (such as anemia, neutropenia). This feature also makes filgotinib a more targeted treatment option suitable for patients taking long-term medication.

In summary, filgotinib blocks the signaling of inflammatory factors by highly selectively inhibiting JAK1, effectively reducing the clinical symptoms of patients with autoimmune diseases and improving the quality of life to a certain extent. During use, blood routine and liver and kidney functions should be monitored regularly according to the guidance of a doctor to ensure safe and effective treatment.

Reference materials:https://go.drugbank.com/drugs/DB14845